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Deterioration of Cycloserine in the Tropics*
K. V. NAGESWARA RAO,1 L. EIDUS,2 C. EVANS,3 S. KAILASAM,
S. RADHAKRISHNA, P. R. SOMASUNDARAM, H. STOTT,4 S. SUBBAMMAL & S. P. TRIPATHY
Gross deterioration of cycloserine during transit and storage in the tropics is reported
from the Tuberculosis Chemotherapy Centre, Madras. Laboratory experiments suggest
that high humidity, rather than high temperature, is the main cause of the deterioration.
Further investigations undertaken at the Centre indicate that deterioration can be prevented
by storing the drug in tightly closed glass bottles in an air-conditioned room (18°C) ; if
such facilities are not available, and the drug has to be stored at ambient temperature and
humidity, the use of air-tight polyethylene bottles will serve to delay the deterioration. The
findings also suggest that, when cycloserine is dispensed to patients, individual doses should
be heat-sealed in polyethylene strips and that not more than a week’s supply should be
given at any one time. The authors discuss various measures that could be employed by
manufacturers and by shipping and clearing agents to minimize the possibility of
deterioration.
Cycloserine is frequently used in the re-treatment
of patients with pulmonary tuberculosis who have
failed to respond to standard chemotherapy, and
cycloserine in combination with ethionamide is the
basis of a valuable regimen (Brouet et al., 1959;
Veran et al., 1959; British Tuberculosis Associa-
tion, 1961; Schwartz, 1962; Salomon &Gold, 1963;
Ramakrishnan et al., 1967). During a therapeutic
study of the combination at this Centre, a major
deficit in the stated content of cycloserine in tablets
was detected. The present paper describes the dis-
covery of this deficit, which was caused by deteriora-
tion of the drug, and the subsequent field and
laboratory investigations undertaken to determine
the rate at which deterioration occurred, its causes
and ways in which it could be prevented or delayed.
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DISCOVERY OF CYCLOSERINE DEFICIT
Receipt, storage and dispensing of cycloserine at the
Centre
Supplies of cycloserine arrived at the Centre
either by air, taking 1-3 weeks after despatch from
the factory, or by sea, usually taking 2-3 months.
The cycloserine was supplied as 250-mg tablets
or 250-mg capsules in amber-coloured screw-capped
bottles, each containing 500. These bottles were
kept in a store at ambient temperature and humidity,
and issued to the outpatient clinic at approximate&
weekly intervals, according to requirements.
The cycloserine was administered under super-
vision to patients treated in sanatorium and to
ambulatory patients who attended the Centre daily.
For the other patients, who attended the Centre once
weekly or twice weekly and self-administered the
drug at home, a supply of cycloserine for a week, or
for 3 or 4 days, was dispensed in paper envelopes.
Deterioration of cycloserine tablets stored in the
Centre
Up to September 1964, only capsules of cyclo-
serine were used at the Centre and no urine-testing
for the drug was performed. At this stage, the use
of tablets was introduced and, by coincidence, urine
tests for cycloserine, using the method of Rao et al.
(1965), were started for patients receiving the drug.
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Until April 1965, the urine-test results for patients
in the sanatorium (who received the cycloserine tablets
daily under supervision) were almost always positive.
However, towards the end of April, very many
negative results were reported. This finding was so
much at variance with the established reliability
of the test (Rao et al., 1965) that, after preliminary
investigations had excluded laboratory errors or
inadequate supervision as possible causes, it was
decided to assay the tablets in current use by the
colorimetric method of Jones (1956), using pure
cycloserine 1 as the standard. The tablets that were
assayed were taken from a batch of 50 bottles,
marked with an expiry date of April 1966, which
had arrived at the Centre by air in October 1964.
It was found that the screw caps of many of the
33 bottles remaining in the store from this batch
were loose, and that the tablets smelt strongly of
ammonia. Further, the tablets were discoloured
yellow and were stuck to one another, as well as to,
the cotton packing in the bottles. From the 33 bot-
tles, 7 were selected by a systematic sampling pro-
cede, starting from the second and thereafter
selecting every fifth bottle, and 1 tablet taken indis-
criminately from each of these bottles was assayed.
The cycloserine content ranged from 6 mg to 142 mg,
the mean for the 7 bottles being 77 mg, that is,
31% of the stated content of 250 mg.
During the period of storage (October 1964-
April 1965), the daily temperature 2 in Madras
ranged from 23°C to 31°C (mean, 27°C). The
daily relative humidity 2 ranged from 56 % to 95 %
(mean, 76%) and the maximum at any time during
the period was 100%. Thus, the tablets had been
exposed to high temperatures and, especially those
in bottles with loose caps, to high humidity also;
it was subsequently realized that storage under such
conditions was contrary to the recommendation that
“ cycloserine should be kept in a well-closed con-
tainer, protected as far as possible from moisture,
and stored at a temperature not exceeding 25°C ”
(British Pharmacopoeia, 1963). However, the only
instruction on the labels of the bottles was “ store
in a cool place ”.
Potency of cycloserine tablets on arrival at the Centre
Sea freight. Two consignments of cycloserine
tablets were received at the Centre by sea after
1 Pure cycloserine was supplied by the manufacturers in
powder form in heat-sealed, amber-coloured ampoules.
At the Centre, the ampoules were stored in a cold-room at
a temperature of approximately 9°C.
2 Mean of 24 readings, recorded at hourly intervals.
the assays were started. The first, consisting of
50 bottles (each containing 500 tablets) with an
expiry date of May 1966, took about 6 months
in transit, from December 1964 to June 1965. On
arrival, the caps of many of the bottles were loose,
and the tablets smelt strongly of ammonia, were
tacky and were discoloured yellow. Assay of single
tablets, taken indiscriminately from each of the
50 bottles, showed that the cycloserine content
ranged from 12 mg to 225 mg, the mean content
for the sample being 130 mg, that is, 52% of the
stated content of 250 mg. The tablets in the second
consignment (60 bottles, each containing 500 tablets),
which took about 2 months in transit between June
and August 1965, had a satisfactory appearance on
arrival and the mean cycloserine content of a
sample of 24 tablets (2 from each of a random
sample of 12 bottles) was found to be 257 mg.
No consignment of capsules arrived by sea after
assays were started.
Air freight. Two bottles of cycloserine tablets and
2 of capsules, each bottle containing 500, were
received at the Centre by air in July 1965 for experi-
mental purposes. Assays undertaken on 25 tablets
and 25 capsules showed that the mean cycloserine
content was 260 mg in tablets and 259 mg in cap-
sules. In August 1965, a consignment of 30 bottles,
each containing 500 capsules, arrived by air; the
mean cycloserine content of 18 capsules (3 from
each of a random sample of 6 bottles) was found
to be 250 mg.
FIELD AND LABORATORY INVESTIGATIONS
Storage in the Centre under various condition and
in patients’ homes
An investigation was undertaken to determine
whether the cycloserine content of tablets and cap-
sules was affected by storage and, if so, the relative
importance of (1) storage conditions, (2) type of
container used for storage, and (3) duration of
storage. The tablets and capsules used in this and
subsequent investigations were taken from the 4 bot-
tles received by air for experimental purposes (see
above), which were stored in the laboratory cold-
room at a temperature of approximately 9°C and
a relative humidity of approximately 75%.
A supply of tablets was placed in (1) an original
(manufacturer’s) glass bottle (screw-capped, tightly
closed and with cotton packing inside) in an air-
conditioned room (temperature 18°C, relative humid-
ity 55%), (2) a tightly closed screw-capped poly-
783DETERIORATION OF CYCLOSERINE IN THE TROPICS
TABLE 1
DETERIORATION OF CYCLOSERINE DURING STORAGE IN THE CENTRE AND UNDER VARIOUS
CONDITIONS IN PATIENTS’ HOMES
Mean cycloserine content (%) a in following no. of days: b
Place of storage C o n t a i n e r  
1  2  4  7  14  21  23  42  56
Air-conditioned room  Glass bottle    100
Clinic Polyethylene bottle    102
Clinic Glass bottle  101
Clinic Paper envelopes  101
Patient’s home (1) : Paper envelopes  98
Patient’s home (2) Paper envelopes  100
Air-conditioned room   Glass bottle 102
Clinic  Polyethylene bottle   103
Clinic Glass bottle       102
Clinic Paper envelopes 101
Patient’s home (1) Paper envelopes 101





















99 99 100 102
100 99 99 101


































a Expressed as a percentage of the mean cycloserine content of the 36 control tablets (261.5 mg) or the 35 control capsules
(259.2 mg) that were assayed, 4 on each of the 9 occasions.
b Parentheses indicate that the cycloserine content is less than the minimum BP. limit of 231.25 mg for tablets and 225.0 mg
for capsules. Italics indicate that the loss in cycloserine content is statistically significant at the 1 % level. As the variance of the
cycloserine content of replicate tablets or capsules stored under identical conditions (container, temperature, and humidity), differed
from one storage condition to another (data not presented here), the magnitude of the decrease required for statistical significance













ethylene bottle (100 ml) in the clinic, (3) an original
glass bottle (described in (1) above) in the clinic,
(4) paper envelopes, each containing 4 tablets, in the
clinic, and (5) paper envelopes, each containing
4 tablets, in the homes of 2 patients.
It was planned to assay 4 tablets from each container
and, as a control on laboratory standards, from the
stocks in the laboratory cold-room, 1, 2, 4, 7, 14,
21, 28, 42 and 56 days after storage. (As it hap-
pened, the cycloserine content in tablets stored in
patient-s’ homes was so low at 14 days (see Table 1)
that subsequent assay of tablets from this source
was discontinued.) On each of these days, all the
tablets for assay were sent with code numbers and
in a random order to the biochemist, thereby
ensuring that he was unaware of the identity of any
of the individual tablets or, indeed, which tablets
had been stored under the same conditions. Iden-
tical procedures were employed for capsules. During
the period of this investigation, the daily temperature
in Madras ranged from 25°C to 31°C and the rela-
tive humidity from 74% to 98%, the means being
28°C and 85%; the maximum relative humidity
was 90 % or above on all days and 100% on as
many as 23 days.
There was no evidence of changes in laboratory
standards during the course of this, or any subse-
quent, investigation; thus, the variation, from one
day to another, in mean cycloserine content of the
4 control tablets or capsules was no more than
the variation in content between replicate tablets or
capsules assayed on the same day. Consequently,
in each investigation, the cycloserine content after
a period of storage has been expressed as a per-
centage of the mean content of all the control
tablets or capsules in the investigation-that is, the
latter has been regarded as the initial content.
In this report, the earliest occurrence of a statisti-
cally significant decrease (at the 1% level) 1 in cyclo-
1 Since the effect of storage could only be a loss in cyclo-
serine content, one-tail tests of significance were employed.
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serine content has been taken as the first indication
of deterioration, except on occasions when there
was a conflicting finding at the next assessment.
A second criterion, namely, a fall in cycloserine
content to below the B.P. limit, has also been
employed; this limit, which is based on tolerances
for manufacturing variations, is 92.5% (i.e.,
231.25 mg) for tablets and 90.0% (i.e., 225.0 mg)
for capsules (British Pharmacopoeia, 1963, 1966).
Tablets. No deterioration occurred in the tablets
stored in the glass bottle in the air-conditioned
room (Table 1). Considering the various containers
at ambient temperature and humidity in the clinic,
no deterioration was detected after storage in the
polyethylene bottle but tablets stored in the glass
bottle had deteriorated by 21 days and the mean con-
tent fell below the B.P. limit by 42 days; with paper
envelopes, deterioration occurred by 4 days, and the
mean content fell below the B.P. limit by 21 days
and was as low as 8% at 56 days. However, the
deterioration was greatest when the tablets were
stored in paper envelopes in patients’ homes: the
cycloserine content fell below the B.P. limit by 7 days
in both cases, and was only 33 % and 4 %, respec-
tively, at 14 days.
Capsules. As with tablets, no deterioration oc-
curred in the capsules stored in the glass bottle in
the air-conditioned room. Capsules in the poly-
ethylene bottle in the clinic showed deterioration
at 42 days but the cycloserine content did not fall
below the B.P. limit even at 56 days. The mean
content of capsules in the glass bottle in the clinic
fell below the B.P. limit by 21 days, the deterioration
having first been detected at 4 days. Finally, as in
tablets, the deterioration was swift and striking
in capsules stored in paper envelopes, especially at
patients’ homes : deterioration was detected at
7 days in the clinic and in 2 days in both the homes,
and the mean content fell below the B.P. limit by 14
and 7 days, respectively.
In summary, storage in tightly closed glass bottles
in’ an air-conditioned room prevented the deteriora-
tion of cycloserine over a period of at least 56 days,
in spite of the bottles having been opened on
9 occasions to take out tablets or capsules. Storage
in a tightly closed polyethylene bottle at ambient
temperature and humidity prevented the deteriora-
tion over a period of 28 days, Finally, storage in
paper envelopes was very unsatisfactory: deteriora-
tion occurred within 48 hours and virtually no
















paper envelopes (%) a
Tablets b Capsules b Tablets b  Capsules b
95 94 99 101
95 (83) 98 99
94 (77) 100 97
(83) (66) 97 96
(75) (55) 95 95
(59) (33) 101 96
(16) (10) 100 95
– – 101 92
– – 96 (83)
– – 97 (77
TABLE 2
SUITABILITY OF UNIVERSAL CONTAINERS







a The mean content of the tablets or capsules stored in the
homes of the 3 patients was computed, and is expressed as a
percentage of the mean cycloserine content of the 40 control
tablets (258.8 mg) or the 40 control capsules (262.8 mg) that
were assayed, 4 on each of the 10 occasions.
b Italics indicate that the loss in cycloserine content is
statistically significant at the 1 % level. Parentheses indicate that
the cycloserine content is less than the minimum B.P. limit of
231.25 mg for tablets and 225.0 mg for capsules.
Storage in different containers in patients’ homes
In order to prevent, or at least delay, the deteriora-
tion of cycloserine when stored in patients’ homes,
the suitability of screw-capped Universal containers
(which were more readily available at the Centre
than polyethylene bottles) and heat-sealed polyethy-
lene bags (prepared by nurses at the Centre) was
investigated.
Universal containers. In each of 3 homes, a supply
of tablets was placed in a screw-capped Universal
container and, as a control to confirm the occurrence
of deterioration, in paper envelopes (each contain-
ing 2 tablets). It was planned to assay, 2, 3, 4,
5, 6, 7, 11, 14, 21 and 28 days after storage, 2 tablets
from each container in each home and, as a control
on laboratory standards, 4 tablets from the stocks
in the laboratory cold-room; in the event, however,
the assay of tablets stored in paper envelopes was
discontinued after 11 days since the cycloserine
content had fallen below 20% by that time (see
Table 2). Each day, all the tablets for assay were
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TABLE 3
SUITABILITY OF POLYETHYLENE BAGS FOR STORAGE
OF CYCLOSERINE IN PATIENTS’ HOMES
 Mean cycloserine
content when
Duration stored in paper when stored in
envelopes polyethylene bags
(%) a (%) a
Tablets b  Capsules b Tablets b  Capsules b
- -
a The mean content of the tablets or capsules stored in the
homes of the 6 patients was computed, and is expressed as a
percentage of the mean cycloserine content of the 16 control
tablets (258.0 mg) or the 16 control capsules (261.4 mg) that
were assayed, 4 on each of the 2 occasions for the 2 sets of
homes (see text).
b Italics indicate that the loss in cycloserine content is
statistically significant at the 1% level. Parentheses indicate
that the cycloserine content is less than the minimum B.P.
limit of 231.25 mg for tablets and 225.0 mg for capsules.
sent under code numbers and in a random order
to the biochemist. An identical experiment was
concurrently undertaken with capsules. During the
period of this investigation, the daily temperature
in Madras ranged from 25°C to 28°C and the
relative humidity from 69% to 98%, the means
being 27°C and 84%, respectively; the maximum
relative humidity was 90% or above on all days.
The findings are set out in Table 2 and are based
on the mean cycloserine content for the 3 homes.
In the case of paper envelopes, deterioration was-de-
tected even at 2 days, both in tablets and in capsules;
further, the mean content fell below the B.P. limit
at 5 and 3 days for tablets and capsules respectively.
In contrast, with Universal containers, deterioration
was detected only at 21 days in tablets and 11 days
in capsules; also, the mean content for tablets was
above the B.P. limit even at 28 days while that for
capsules fell below the B.P. limit by 21 days. Thus,
the Universal containers succeeded in delaying, but
not preventing, deterioration.
Polyethylene bags. In each of 6 homes, a supply
of tablets was placed in heat-sealed polyethylene
bags (each containing 2 tablets) and, as a control
to confirm the occurrence of deterioration, in paper
envelopes (each containing 2 tablets). At 7 and
at 14 days after storage, 1 bag and 1 envelope
were withdrawn, together with 4 control tablets
from the stocks in the laboratory cold-room, and
assays were undertaken after codification and ran-
domization. (The investigation was commenced in
3 homes, and 6 days later 3 more homes were
included.) An identical experiment was concurrently
undertaken with capsules. During the period of this
investigation, the daily temperature in Madras ranged
from 24°C to 28°C and the relative humidity from
69% to 96%, the means being 26°C and 84%,
respectively; the maximum relative humidity was
90% or above on all days.
The findings are set out in Table 3 and are based
on the mean cycloserine content for the 6 homes.
Considering first the paper envelopes, the mean
content at 7 days showed a statistically significant
decrease and was also lower than the B.P. limit, both
for tablets and for capsules. In contrast, the mean
content was 98 % (range, 97 %-101 %) for the tablets
and 97 % (range, 94 %-100%) for the capsules which
were stored in polyethylene bags. This suggests
that the polyethylene bags were largely successful
in preventing deterioration up to 7 days. However,
at 14 days, definite deterioration was detected, the
mean content being 92% (range, 88 %-97 %) for
tablets and 87 % (range, 77%-96%) for capsules.
Even so, an examination of the data for individual
homes (not tabulated here) showed that the mean
content had fallen below the B.P. limit in only
2 instances, and in both, only in capsules.
Summarizing the findings of both the investiga-
tions in patients’ homes, there was clear evidence
that the storage of cycloserine tablets, and to a lesser
extent capsules, in tightly closed screw-capped Uni-
versal containers or heat-sealed polyethylene bags
delayed, but did not prevent, deterioration of
the drug.
Relative speed and magnitude of deterioration of
tablets and capsules
A comparison of the speed and extent of deteriora-
tion of tablets and capsules, abstracted from the data
in Tables 1 and 2, is given in Table 4.
Considering first the storage of cycloserine at
ambient temperature and humidity in the clinic,
the difference in mean content between tablets and
capsules was highly significant at 2 days (P=0.001)
and subsequently. Further, the mean content fell
below the B.P. limit by 42 days for tablets and by
21 days for capsules. The mean content of cyclo-
serine stored in homes was -significantly higher at
3 days in tablets than in capsules (P<0.01); subse-
quently, it fell below the B.P. limit at 6 days for
tablets compared with 5 days for capsules. These
findings demonstrate that the deterioration of cyclo-
serine capsules was more rapid and more substantial
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TABLE 4
RELATIVE SPEED AND MAGNITUDE OF DETERIORATION OF CYCLOSERINE IN TABLETS AND CAPSULES
Container and place Form of i Mean cycloserine content (%) in following no. of days: LL
of storage cycloserine
1 2 3 4 5 6 7 11 14 21 28 42 56
~__.-
Polyethylene bottles, glass T a b l e t s  I 102 loo - 99 - - 97 - 97 94 91 (71) (Sl
bottles and paper en-
vdopes  in clinic 8 Capsules 102 98 - 97 - - 96 - 88 (79) (76) (47) (33)
Paper envelopes and Uni- i Tablets - 97 97 97 90 (85) (80) (58)
rersal containers in
patients’ homes c / Capsules / - 98 92 88 (82) (75) (65) (53)
a Parentheses indicate that the cycloserine content is less than the minimum B.P.limit of 231.25 mg for tablets and 225.0 mg
for capsules. 8 Data from Table 1. C Data from Table 2.
than that of tablets, both in the clinic and in
patients’ homes.
Laboratory  investigations of the effect of temperature
and humidity
Investigations were undertaken in the laboratory
to determine the roles of temperature and humidity
in causing deterioration of cycloserine. A desiccant,
phosphorous pentoxide, was placed at the bottom
of each of 4 screw-capped honey-jars, and water in
each of 4 others. A small beaker containing 4 tablets
of cycloserine was placed in each of the 8 jars,
and the screw caps of those containing the desiccant
were sealed with wax while those of the jars con-
taining water were left loose. All the jars were placed
in an incubator at 39°C and it was planned to assay
-1 tablet from each jar at 4, 15, 22 and 30 day8 after
storage, together with 4 control tablets from the
stocks in the laboratory cold-room. An identical
investigation was undertaken concurrently with
capsules.
No deterioration occurred over the 30-day period
in tablets and capsules exposed to a temperature
of 39°C in a dry atmosphere (Table 5); in contrast,
TABLE 5
LABORATORY INVESTIGATIONS OF THE EFFECT OF TEMPERATURE AND HUMIDITY ON CYCLOSERINE
CONTENT OF TABLETS AND CAPSULES
Experiment Packaging and Relativestoring conditions humidity
Tem- Mean cycloserine Mean cycloserine
pera- content (%) a of tablets content (%) a of capsules
ture in following no. of days: b in following no. of days: b
w 4 / 15 1 22 1 30 4 / 15 / 22 / 30
--.--~
Loose in presence
of desiccant Negligible 39 101 100  100  98 98 ’ 99 / 99 j 99
Loyfe;;tpesence
Approx. 100 % 39 (3) - - - (2)  - - -
---~- ~ - -.- I__
2 I Loyfe;;tepesence
Approx. 100  % 25 (4) - - -
(3)  I - - --~---__
t I---  - - - ‘ -
Foil-packed in presence
I of desiccant Negligible 39 102 102 104 103
3 1 1 I
: Foit$acaye;  in presence
Approx. 100  % 39 103 (89) @a (56)
~ I I
c Expressed as a percentage of the mean cycloserine content of all the control tablets or all the control capsules that were
assayed during the course of the experiment; the means were 266.4 mg. 268.8 mg and 254.7 mg for tablets in experiments I,2 and
3, respectively, and 259.8 mg and 260.2 mg for capsules in experiments 1 and 2, respectively.
* Italics indicate that the loss in cycloserine content is statistically significant at the I % level. Parentheses indicate that the
cycloserine content is less than the minimum B.P. limit of 231.25 mg for tablets and 225.0 mg for capsules.
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virtually no cycloserine remained at 4 days (and
consequently, no further assays were done) in tablets
and capsules stored in saturated air at the same
temperature (39°C) or indeed (as shown by the
results of a second experiment), at a lower tempera-
ture (25°C). Finally, a third experiment, employing
tablets sealed in aluminium foil strips by the manu-
facturer and stored at 39°C, showed that no deterio-
ration occurred in a dry atmosphere, but in saturated
air, deterioration occurred and the cycloserine con-
tent fell below the B.P. limit by 15 days. These
results suggest that high humidity is a more import-
ant cause of deterioration of cycloserine than high
temperature, and that the dispensing of cycloserine
tablets in aluminium foil strips can





This paper reports deterioration of cycloserine
which occurred during transit and storage in the
tropics, and has shown that loss in cycloserine con-
tent can occur if tablets or, more particularly,
capsules of cycloserine are exposed to atmospheric
conditions of high humidity and high temperature.
Further, laboratory investigations suggest that high
humidity plays a more important part in causing
deterioration than high temperature.1 Finally, it has
been shown that it is possible (a) to prevent the
deterioration of cycloserine by storing the tablets or
capsules in tightly closed glass bottles in an air-
conditioned store (18°C), and (b) to delay the deterio-
ration by storing the drug in air-tight screw-capped
polyethylene bottles in the clinic (at ambient temper-
ature and humidity) or dispensing it to patients in
screw-capped Universal containers or in beat-sealed
polyethylene bags.
In view of the possibility of deterioration, manu-
facturers should label bottles of cycloserine promi-
nently with the appropriate storage requirements.2
However, as it is often difficult in developing coun-
tries in the tropics to conform to these requirements,
it is important that manufacturers should provide
suitable packing, especially to protect against high
humidity. (The bottles should have tight-fitting
sealed caps as a minimum requirement, and the
addition of a desiccant would be advantageous.2
1 This has been confirmed independently by the manufac-
turers of cycloserine capsules (Rice, personal communication).
2 Since our findings were made known, bottles of cyclo-
serine tablets arriving at the Centre have labels clearly
specifying the storage requirements, contain a desiccant
and have polyethylene snap-caps sealed with metal foil.
Strip packs of polyethylene or aluminium foil,
which in bulk should be packed in air-tight contain-
ers, would also afford some protection, but would
increase the cost by about 5%.) It is also important
to ensure that the drug is not exposed to adverse
conditions in transit, and consignments of cyclo-
serine should therefore be prominently marked to
ensure storage in a dry and preferably cool place.
Finally, it is necessary to treat consignments of
cycloserine as perishable goods and avoid delay in
docks or warehouses, or if delay is unavoidable,
to ensure that the drug is stored under suitable
conditions.
Despite all precautions taken by the manufacturer
and the shipping and clearing agents, medical stores
in the tropics should aim to provide suitable storage
conditions and arrange that only limited supplies of
the drug are issued at any one time to clinics and
hospitals, unless they have suitable storage facilities.
In many tropical countries, it is usual for patients
to receive antituberculosis drugs in a paper envelope
or just wrapped in paper. Our investigations have
shown that these methods are very unsatisfactory
for dispensing cycloserine (for instance, when tablets
and capsules were stored in paper envelopes in
patients’ homes, deterioration occurred in as short a
period as 48 hours), and have suggested 2 better
methods. One is to dispense no more than a week’s
supply at a time in air-tight containers; the effective-
ness of this measure will, however, depend on the
patient’s remembering to close the container tightly
after each dose. The other is to dispense the week’s
supply in moisture-proof strips of aluminium foil or
polyethylene, in which the individual tablets or cap-
sules are sealed in separate compartments. Such a
measure, apart from being more workable, will save
time in the dispensary. However, certain special
precautions would have to be taken with aluminium
foil strips since they are liable to crack if folded or
handled roughly, leaving minute perforations through
which moisture can be readily absorbed.
There is clearly a need for periodic verifications
of the potency of cycloserine in tropical conditions..
Ideally, assays of the drug content should be under-
taken, both on receipt and at intervals thereafter.
However, facilities for quantitative assay are often
not available in developing countries in the tropics.
In these circumstances, a simple qualitative test,
capable of detecting a loss in drug content of about
15 % or more (Rao, Kailasam & Nair, 1968) may be
employed. If the deterioration is gross, it can be
detected by simple inspection in the case of tablets
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since they turn yellow (from white), become tacky
and smell of ammonia. Lastly, it must he emphasized
that although a high number of negative urine-test
results in patients receiving cycloserine under
supervision drew our attention to the possibility of
cycloserine deterioration, urine-testing (employing
the method of Rao et al., 1965) is unsuitable for
monitoring potency as the-urine test yields positive
results at 24 hours even when the content of the
tablets is about 80% (unpublished observations).
Our findings have shown that the deterioration
of cycloserine is more rapid and more substantial
in capsules than in tablets; this is presumably because
the drug is pressed firmly with adjuvants in the case
of tablets and thereby acquires some protection
against humidity, while in capsules it is in powder
form.
In conclusion, evidence is presented in this paper
that loss in content of cycloserine tablets and cap-
sules may occur in a tropical climate with high
humidity and high temperature. Such an occurrence
could have serious effects since the deteriorated
product is inactive 1 and since cycloserine is a drug
in which the margin between adequate and inade-
quate dosage is probably small (Canetti, 1964);
furthermore, this drug is usually prescribed to
patients who have been unsuccessfully treated with 1,
or even 2, previous regimens of chemotherapy. It is
therefore imperative that all possible precautions
should be taken to prevent deterioration of cyclo-
serine, both in transit and subsequently.
1 Microbiological assays, using Mycobacterium tuber-
culosis H37Rv and Staphylococcus aureus as test organisms,
were undertaken on tablets and capsules which were found
to be deficient in content by the colorimetric method;
they showed a corresponding loss in the inhibitory activity
of cycloserine, indicating that the deteriorated product was
inactive in vitro.
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Les auteurs rapportent les résultats de leurs reeherches
sur la deterioration de la cyclosérine pendant son trans-
port et son stockage à Madras (Inde) où la temperature et
l’humidité sont généralement élevées.
Une enquête, au cours de laquelle des comprimés et des
capsules de cyclosérine ont été conserves dans diverses
conditions pendant une période de 56 jours, a montré que:
a) la conservation en flacons de verre hermétiquement
fermés, dans une pièce climatisée, empêche la deteriora-
tion du produit pendant une période d’au moins 56 jours;
b) la conservation en flacons de polyethylene hermétique-
ment fermés, au dispensaire, dans les conditions de
temperature et d’humidité ambiantes, prévient la deterio-
ration du produit pendant une période de 28 jours;
c) la conservation dans des enveloppes de papier aboutit
à une détérioration rapide, en particulier au domicile des
malades où la teneur moyenne en cyclosérine des compri-
més et des capsules descend en 7 jours au-dessous des
limites prescrites par la Pharmacopée britannique.
Lorsqu’ils sont gardés au domicile des malades dans des
recipients hermétiquement fermés par des couvercles à vis,
les comprimés ne subissent aucune alteration pendant au
moins 14 jours et les capsules pendant au moins 7 jours; en
outre, la teneur moyenne en cyclosérine reste supérieure
aux limites prescrites par la Pharmacopée britannique
pendant 28 jours dans les comprimés et 14 jours dans les
capsules. En conservant les comprimés et les capsules, au
domicile des malades, dans des sachets de polyethylene
fermés à chaud, on réussit à empêcher la deterioration du
produit pendant un maximum de 7 jours; au bout de
14 jours, bien que l’on puisse constater une nette altera-
tion des comprimés et des capsules, leur teneur moyenne
en cyclosérine reste supérieure à la limite fixée par la
Pharmacopée britannique. Les capsules se détériorent 
plus rapidement et plus fortement que les comprimés.
D’après les données recueillies au laboratoire, il semble
qu’un degré élevé d’humidité relative soit un facteur de
deterioration plus important qu’une temperature élevée.
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